Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.

Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS, Padley RJ.

J Clin Oncol. 2002 Apr 15;20(8):2171-80. Erratum in: J Clin Oncol. 2003 Jun 15;21(12):2449.

PMID:
11956279
2.

A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.

Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC.

Clin Cancer Res. 2001 Oct;7(10):3047-55.

3.

A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.

Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA.

Clin Cancer Res. 2001 Aug;7(8):2292-300.

4.

Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.

Rowinsky EK, Long GS, Noe DA, Grochow LB, Bowling MK, Sartorius SE, Donehower RC.

Clin Cancer Res. 1997 Mar;3(3):401-7.

5.

A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.

Rowinsky EK, Kaufmann SH, Baker SD, Miller CB, Sartorius SE, Bowling MK, Chen TL, Donehower RC, Gore SD.

Clin Cancer Res. 1996 Dec;2(12):1921-30.

6.

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.

Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC.

J Clin Oncol. 1996 Dec;14(12):3074-84.

PMID:
8955652
7.

Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.

Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC.

J Clin Oncol. 1996 Apr;14(4):1224-35.

PMID:
8648378
8.

Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.

Rowinsky EK, Flood WA, Sartorius SE, Bowling MK, Wagner J, Ettinger DS.

Semin Oncol. 1995 Aug;22(4 Suppl 9):48-54.

PMID:
7644928
9.

Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.

Rowinsky EK, Noe DA, Grochow LB, Sartorious SE, Bowling MK, Chen TL, Lubejko BG, Kaufmann SH, Donehower RC.

J Clin Oncol. 1995 Aug;13(8):1975-84.

PMID:
7636538
10.

Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.

Slichenmyer WJ, Donehower RC, Chen TL, Bowling MK, McGuire WP, Rowinsky EK.

Cancer Chemother Pharmacol. 1995;36(3):227-32.

PMID:
7781143

Supplemental Content

Loading ...
Support Center